Log in
NASDAQ:ARVN

Arvinas Stock Forecast, Price & News

$20.91
-1.01 (-4.61 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$20.50
Now: $20.91
$22.04
50-Day Range
$20.19
MA: $24.26
$27.99
52-Week Range
$19.68
Now: $20.91
$61.57
Volume543,850 shs
Average Volume445,587 shs
Market Capitalization$820.47 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARVN
CUSIPN/A
CIKN/A
Phone203-535-1456
Employees133

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.98 million
Book Value$6.72 per share

Profitability

Net Income$-70,290,000.00
Net Margins-182.59%

Miscellaneous

Market Cap$820.47 million
Next Earnings Date11/2/2020 (Estimated)
OptionableNot Optionable
$20.91
-1.01 (-4.61 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARVN News and Ratings via Email

Sign-up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arvinas (NASDAQ:ARVN) Frequently Asked Questions

How has Arvinas' stock price been impacted by Coronavirus (COVID-19)?

Arvinas' stock was trading at $44.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARVN shares have decreased by 52.5% and is now trading at $20.91.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Arvinas?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arvinas
.

When is Arvinas' next earnings date?

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Arvinas
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.65) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.06. The company earned $5.75 million during the quarter, compared to analysts' expectations of $5.73 million. Arvinas had a negative net margin of 182.59% and a negative return on equity of 31.68%.
View Arvinas' earnings history
.

What price target have analysts set for ARVN?

10 brokerages have issued 12 month price objectives for Arvinas' stock. Their forecasts range from $45.00 to $75.00. On average, they anticipate Arvinas' stock price to reach $59.22 in the next twelve months. This suggests a possible upside of 183.2% from the stock's current price.
View analysts' price targets for Arvinas
.

Who are some of Arvinas' key competitors?

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), Crispr Therapeutics (CRSP), Energy Transfer (ET), Opko Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

Who are Arvinas' key executives?

Arvinas' management team includes the following people:
  • Dr. John G. Houston Ph.D., CEO, Pres & Director (Age 60, Pay $949.5k)
  • Mr. Sean A. Cassidy CPA, CFO & Treasurer (Age 50, Pay $551.9k)
  • Dr. Ronald A. Peck, Chief Medical Officer
  • Dr. Craig M. Crews, Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
  • Dr. Ian Taylor, Chief Scientific Officer (Age 57)

When did Arvinas IPO?

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Canaan Partners IX LLC (10.17%), Candriam Luxembourg S.C.A. (0.82%), DekaBank Deutsche Girozentrale (0.10%), Regents of The University of California (0.04%), Moloney Securities Asset Management LLC (0.03%) and BNP Paribas Arbitrage SA (0.02%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am.
View institutional ownership trends for Arvinas
.

Which major investors are selling Arvinas stock?

ARVN stock was sold by a variety of institutional investors in the last quarter, including Canaan Partners IX LLC, and Candriam Luxembourg S.C.A.. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Ian Taylor, John G Houston, Ronald Peck, and Sean A Cassidy.
View insider buying and selling activity for Arvinas
.

Which major investors are buying Arvinas stock?

ARVN stock was acquired by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, Regents of The University of California, Moloney Securities Asset Management LLC, and BNP Paribas Arbitrage SA. Company insiders that have bought Arvinas stock in the last two years include Briggs Morrison, Ian Taylor, Liam Ratcliffe, and Timothy M Shannon.
View insider buying and selling activity for Arvinas
.

How do I buy shares of Arvinas?

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $20.91.

How big of a company is Arvinas?

Arvinas has a market capitalization of $820.47 million and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Arvinas employs 133 workers across the globe.

What is Arvinas' official website?

The official website for Arvinas is www.arvinas.com.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.